Cognitive Improvement In Mild To Moderate Alzheimer’s Dementia After Treatment With The Acetylcholine Precursor Choline Alfoscerate: A Multicenter, Double-blind, Randomized, Placebo-controlled Trial

効果 減少
試験方法 二重盲検法
試験期間 6+ ヶ月
被験者数 261
性別 男女
年齢 65+
体型 平均, Underweight
この研究の注釈：

Supplementation of Alpha-GPC at 400mg thrice daily (1,200mg daily) for 180 days in persons with mild to moderate Alzheimer’s disease was able to improve symptoms as assessed by a multitude of rating scales including ADAS, MMSE, CDI, and GDS.